Ribomic (TSE:4591) Research & Development: 円803.99 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4591 Ribomic Inc TSE:4591
32 GF Score
Price 円77.00
! 3 Warning Signs
View Full Analysis

What is Ribomic Research & Development?

Ribomic TSE:4591 +2.67% 32 Research & Development is 円803.99 Mil as of Mar. 2026. GuruFocus rates TSE:4591 with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Ribomic's Research & Development for the three months ended in Mar. 2026 was 円312.96 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was 円803.99 Mil.

Ribomic  (TSE:4591) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ribomic Research & Development Related Terms

Ribomic Research & Development Historical Data

* Premium members only.

The historical data trend for Ribomic's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ribomic Research & Development Chart

Ribomic Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,482.13 1,491.24 764.33 667.69 803.99

Ribomic Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 136.11 197.39 157.52 312.96
TSE:4591
32GF Score
Ribomic Inc TSE:4591
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ribomic Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円803.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円803.99 Mil mean?
Ribomic (TSE:4591) has a Research & Development of 円803.99 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Ribomic and its competitors.
Is Ribomic's Research & Development too high?
Ribomic's current Research & Development is 円803.99 Mil. Overall, Ribomic has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Ribomic's Research & Development compare to VRTX and REGN?
Ribomic's Research & Development of 円803.99 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Ribomic and its competitors. Ribomic's current Research & Development is 円803.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ribomic stock overvalued right now?
Ribomic (TSE:4591) has a current Research & Development of 円803.99 Mil. The current Research & Development is 円803.99 Mil. Ribomic's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Ribomic (TSE:4591), the current Research & Development is 円803.99 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ribomic Business Description

Address 3-16-13 Usui Building, Shirokanedai, Minato-ku, Tokyo, JPN, 108-0071
Ribomic Inc is a biopharmaceutical venture company based in Tokyo. The company is developing molecular targeted pharmaceutical drugs using RNA aptamers with its unique and advanced platform technologies, the RiboART System.
32GF Score

Get the complete analysis for TSE:4591

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円77.00
Price